全文获取类型
收费全文 | 533篇 |
免费 | 41篇 |
国内免费 | 49篇 |
专业分类
耳鼻咽喉 | 5篇 |
儿科学 | 26篇 |
妇产科学 | 18篇 |
基础医学 | 94篇 |
口腔科学 | 16篇 |
临床医学 | 75篇 |
内科学 | 109篇 |
皮肤病学 | 9篇 |
神经病学 | 13篇 |
特种医学 | 53篇 |
外科学 | 92篇 |
综合类 | 23篇 |
一般理论 | 1篇 |
预防医学 | 31篇 |
眼科学 | 3篇 |
药学 | 47篇 |
中国医学 | 1篇 |
肿瘤学 | 7篇 |
出版年
2023年 | 2篇 |
2022年 | 2篇 |
2021年 | 6篇 |
2020年 | 10篇 |
2019年 | 15篇 |
2018年 | 19篇 |
2017年 | 8篇 |
2016年 | 15篇 |
2015年 | 10篇 |
2014年 | 14篇 |
2013年 | 23篇 |
2012年 | 26篇 |
2011年 | 32篇 |
2010年 | 14篇 |
2009年 | 19篇 |
2008年 | 23篇 |
2007年 | 53篇 |
2006年 | 16篇 |
2005年 | 25篇 |
2004年 | 16篇 |
2003年 | 14篇 |
2002年 | 17篇 |
2001年 | 16篇 |
2000年 | 22篇 |
1999年 | 24篇 |
1998年 | 10篇 |
1997年 | 14篇 |
1996年 | 17篇 |
1995年 | 11篇 |
1994年 | 12篇 |
1993年 | 14篇 |
1992年 | 7篇 |
1991年 | 7篇 |
1990年 | 10篇 |
1989年 | 5篇 |
1988年 | 12篇 |
1987年 | 8篇 |
1986年 | 6篇 |
1984年 | 2篇 |
1982年 | 6篇 |
1981年 | 5篇 |
1980年 | 2篇 |
1979年 | 2篇 |
1978年 | 2篇 |
1977年 | 4篇 |
1976年 | 6篇 |
1974年 | 5篇 |
1973年 | 2篇 |
1972年 | 2篇 |
1971年 | 5篇 |
排序方式: 共有623条查询结果,搜索用时 15 毫秒
91.
Hermansen K Davies M Derezinski T Martinez Ravn G Clauson P Home P 《Diabetes care》2006,29(6):1269-1274
OBJECTIVE: To assess efficacy and tolerability of insulin detemir or NPH insulin added to oral therapy for type 2 diabetes in a treat-to-target titration protocol. RESEARCH DESIGN AND METHODS: Individuals (n = 476) with HbA(1c) (A1C) 7.5-10.0% were randomized to addition of twice-daily insulin detemir or NPH insulin in a parallel-group, multicenter trial. Over 24 weeks, insulin doses were titrated toward prebreakfast and predinner plasma glucose targets of < or =6.0 mmol/l (< or =108 mg/dl). Outcomes assessed included A1C, percentage achieving A1C < or =7.0%, risk of hypoglycemia, and body weight. RESULTS: At 24 weeks, A1C had decreased by 1.8 and 1.9% (from 8.6 to 6.8 and from 8.5 to 6.6%) for detemir and NPH, respectively (NS). In both groups, 70% of participants achieved an A1C = 7.0%; [corrected] there was a trend towards [corrected] the proportion achieving this without hypoglycemia being [corrected] higher with insulin detemir than with NPH insulin (34% [corrected] vs. 25[corrected]%, P = 0.052[corrected]). Compared with NPH insulin, the risk for all hypoglycemia with insulin detemir was reduced by 47% (P < 0.001) and nocturnal hypoglycemia by 55% (P < 0.001). Mean weight gain was 1.2 kg with insulin detemir and 2.8 kg with NPH insulin (P < 0.001), and the difference in baseline-adjusted final weight was -1.58 (P < 0.001). CONCLUSIONS: Addition of basal insulin to oral drug therapy in people with suboptimal control of type 2 diabetes achieves guideline-recommended A1C values in most people with aggressive titration. Insulin detemir compared with NPH insulin achieves this with reduced hypoglycemia and less weight gain. 相似文献
92.
Ostrowski SR Ravn P Hoyer-Hansen G Ullum H Andersen AB 《Scandinavian journal of infectious diseases》2006,38(11-12):1028-1032
In search for a serological marker, which may be used to monitor treatment efficacy in patients with extra-pulmonary mycobacterial infections, serum samples were collected prospectively from patients during a 6-months treatment period. The levels of soluble urokinase-type plasminogen activator receptor (suPAR) and soluble tumour necrosis factor receptor II (sTNFrII) were measured and compared with erythrocyte sedimentation rate (SR) and C-reactive protein levels (CRP). sTNFrII levels were elevated at the time of diagnosis and declined in parallel with traditional inflammation markers (SR and CRP). suPAR levels were elevated to more than double (median 7.7 ng/ml, range 5.6-25.8) compared to levels previously reported for patients with pulmonary tuberculosis. The serum suPAR levels however remained high during the entire treatment period. This may reflect that significant inflammatory activity is continuing for more than 6 months in patients with extrapulmonary mycobacterial infections, despite adequate anti-tuberculosis treatment. 相似文献
93.
Larsen M Jensen KB Christensen PA Suarez E Paris D Sanz L Ravn P Sauce D Saas P Goletz S Alvarez-Vallina L Kristensen P 《Journal of immunological methods》2008,339(2):220-227
Antibodies capable of recognizing key molecular targets isolated e.g. by phage display technology have been used in the pursuit of new and improved therapies for prevalent human diseases. These approaches often take advantage of non-immunogenic antibody fragments to achieve specific toxin-, radioactivity- or effector-domain delivery. There is now a growing interest in using anti-idiotypic antibodies or other antigen mimics to induce potent immune responses against antigen structures in question. We have earlier reported on the functional rescue of antibodies that are active when fused to the phage, but inactive as soluble protein [Jensen, K.B., Larsen, M., Pedersen, J.S., Christensen, P.A., Alvarez-Vallina, L., Goletz, S., Clark, B.F. and Kristensen, P. (2002) Functional improvement of antibody fragments using a novel phage coat protein III fusion system. Biochem. Biophys. Res. Commun. 298, 566-73.]. The rescue was accomplished by maintaining the fusion between the antibody fragment and portions of the filamentous bacteriophage coat protein 3, as present in the original antibody-displaying phage. In the present study, we have applied this system in an attempt to improve immunogenicity of anti-idiotypic antibodies isolated by phage display. Here we demonstrate that by preserving linkage between phage antibody and the N-terminal domain of phage coat protein 3, we induce multimerization of the antibody fragments, and improve their immunogenicity. This immunization approach allows induction of anti-idiotypic antibodies in mice, and facilitates the use of antibodies that are non-functional as non-fused soluble protein. 相似文献
94.
95.
Many documents describe standardized methods and standard equipment requirements in the field of audiology and hearing aids. These standards will ensure a uniform level and a high quality of both the methods and equipment used in audiological work. The standards create the basis for measuring performance in a reproducible manner and independent from how and when and by whom parameters have been measured. This article explains, and focuses on, relevant acoustic and electromagnetic compatibility parameters and describes several test systems available. 相似文献
96.
Ravn HB Møldrup U Ilkjaer LB Chew M Jensen L Johnsen S Birk-Sørensen L Tønnesen E Hjortdal VE 《APMIS : acta pathologica, microbiologica, et immunologica Scandinavica》2000,108(5):373-379
BACKGROUND: The purpose of the present study was to describe infarct size and platelet accumulation when reperfusion injury was combined with a thrombogenic lesion in the coronary artery. The left anterior descending artery was damaged in 11 pigs and subsequently occluded proximal to the lesion for 50 min, followed by 4 h of reperfusion. RESULTS: The infarct size/area at risk was 40 (35 63)%. Infarct size correlated with troponin-T-3 h (p=0.85, p<0.002), but not with creatine kinase-3 h. Platelet aggregation decreased by 34% (p<0.01) at 15 min of reperfusion, but returned to baseline. Platelet accumulation in the left ventricle was significantly higher in the area at risk (194 (157-206)%) compared to the right ventricle (137 (120-142)%); p<0.05). CONCLUSION: A decreased platelet reactivity and increased accumulation of platelets in the area at risk indicates that activated platelets become entrapped in the myocardium. Troponin-T was a better marker of myocardial damage than creatine kinase in this in vivo model with pigs. 相似文献
97.
Aim: To evaluate the efficacy and safety of a new transdermal continuous combined hormone replacement therapy (HRT) for the prevention of postmenopausal osteoporosis. Methods: 212 osteopenic (lumbar spine and/or hip (femoral neck) bone mineral density (BMD) between −1.0 and −2.5 S.D. of the premenopausal mean value) postmenopausal women aged 45–65 years participated in a 2-year prospective study. Treatments were 45 μg 17β-estradiol combined with 30 (n = 69) or 40 μg (n = 72) levonorgestrel daily or placebo (n = 71) given as a 7-day patch. All received a daily supplement of 500 mg calcium. BMD at lumbar spine (L2–L4), hip and total body, as well as blood and urinary biochemical markers of bone turnover (serum osteocalcin (sOC), serum bone-specific alkaline phosphatase (sBSAP), urinary calcium (uCa) and urinary CrossLaps (uCTX)) were measured regularly. Results: BMD at the lumbar spine, hip and total body increased by 8, 6 and 3% (P < 0.001), respectively, in the hormone groups versus placebo. The bone markers all decreased accordingly (sOC: 37%, sBSAP: 34% and uCTX: 65% from baseline (all P < 0.001)), except for uCa that did not change significantly. No significant dose-related effect of levonorgestrel was found. Vaginal bleeding/spotting decreased from 48 to 25% of the HRT-treated women during the study period. Skin tolerance was good in 84% of the women with no difference between the study groups. No incidences of endometrial hyperplasia, uterine or mammary cancer occurred. Conclusion: The transdermal combination of 17β-estradiol and levonorgestrel has a positive effect on BMD in an osteopenic postmenopausal population. Furthermore, a high safety profile was observed. 相似文献
98.
Comparative evaluation of low-molecular-mass proteins from Mycobacterium tuberculosis identifies members of the ESAT-6 family as immunodominant T-cell antigens 总被引:13,自引:0,他引:13 下载免费PDF全文
Skjøt RL Oettinger T Rosenkrands I Ravn P Brock I Jacobsen S Andersen P 《Infection and immunity》2000,68(1):214-220
Culture filtrate from Mycobacterium tuberculosis contains protective antigens of relevance for the generation of a new antituberculosis vaccine. We have identified two previously uncharacterized M. tuberculosis proteins (TB7.3 and TB10.4) from the highly active low-mass fraction of culture filtrate. The molecules were characterized, mapped in a two-dimensional electrophoresis reference map of short-term culture filtrate, and compared with another recently identified low-mass protein, CFP10 (F. X. Berthet, P. B. Rasmussen, I. Rosenkrands, P. Andersen, and B. Gicquel. Microbiology 144:3195-3203, 1998), and the well-described ESAT-6 antigen. Genetic analyses demonstrated that TB10.4 as well as CFP10 belongs to the ESAT-6 family of low-mass proteins, whereas TB7.3 is a low-molecular-mass protein outside this family. The proteins were expressed in Escherichia coli, and their immunogenicity was tested in cultures of peripheral blood mononuclear cells from human tuberculosis (TB) patients, Mycobacterium bovis BCG-vaccinated donors, and nonvaccinated donors. The two ESAT-6 family members, TB10.4 and CFP10, were very strongly recognized and induced gamma interferon release at the same level (CFP10) as or at an even higher level (TB10.4) than ESAT-6. The non-ESAT-6 family member, TB7.3, for comparison, was recognized at a much lower level. CFP10 was found to distinguish TB patients from BCG-vaccinated donors and is, together with ESAT-6, an interesting candidate for the diagnosis of TB. The striking immunodominance of antigens within the ESAT-6 family is discussed, and hypotheses are presented to explain this targeting of the immune response during TB infection. 相似文献
99.
Zhao G Souers AJ Voorbach M Falls HD Droz B Brodjian S Lau YY Iyengar RR Gao J Judd AS Wagaw SH Ravn MM Engstrom KM Lynch JK Mulhern MM Freeman J Dayton BD Wang X Grihalde N Fry D Beno DW Marsh KC Su Z Diaz GJ Collins CA Sham H Reilly RM Brune ME Kym PR 《Journal of medicinal chemistry》2008,51(3):380-383
A highly potent and selective DGAT-1 inhibitor was identified and used in rodent models of obesity and postprandial chylomicron excursion to validate DGAT-1 inhibition as a novel approach for the treatment of metabolic diseases. Specifically, compound 4a conferred weight loss and a reduction in liver triglycerides when dosed chronically in DIO mice and depleted serum triglycerides following a lipid challenge in a dose-dependent manner, thus, reproducing major phenotypical characteristics of DGAT-1(-/-) mice. 相似文献
100.
Stevo Duvnjak Pernille Ravn Anders Green Poul Erik Andersen 《Cardiovascular and interventional radiology》2016,39(2):204-209